Search ACTG publications from 1/1/2006 to current.


Filter results by

Found 51 results
Filters: First Letter Of Title is I  [Clear All Filters]
Found 51 results.
Skip Alphabet Links A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  


Price P, James I. "IL1A alleles associate with a virological response to antiretroviral therapy in HIV patients beginning therapy with advanced disease." AIDS. 2009;23(9):1173-6.
Sereti I, Dunham RM, Spritzler J, et al. "IL-7 administration drives T cell-cycle entry and expansion in HIV-1 infection." Blood. 2009;113(25):6304-14.
Cimbro R, Vassena L, Arthos J, et al. "IL-7 induces expression and activation of integrin α4β7 promoting naive T-cell homing to the intestinal mucosa." Blood. 2012;120(13):2610-9.
Zhang X, Hunt PW, Hammer SM, Cespedes MS, Patterson KB, Bosch RJ. "Immune Activation While on Potent Antiretroviral Therapy Can Predict Subsequent CD4+ T-Cell Increases Through 15 Years of Treatment." HIV Clin Trials. 2013;14(2):61-7.
Overton ET, Kang M, Peters MG, et al. "Immune response to hepatitis B vaccine in HIV-infected subjects using granulocyte-macrophage colony-stimulating factor (GM-CSF) as a vaccine adjuvant: ACTG study 5220." Vaccine. 2010;28(34):5597-604.
Stüve O, Marra CM, Jerome KR, et al. "Immune surveillance in multiple sclerosis patients treated with natalizumab." Ann. Neurol.. 2006;59(5):743-7.
Haas DW, Geraghty DE, Andersen J, et al. "Immunogenetics of CD4 lymphocyte count recovery during antiretroviral therapy: An AIDS Clinical Trials Group study." J. Infect. Dis.. 2006;194(8):1098-107.
Kojic EMilunka, Kang M, Cespedes MS, et al. "Immunogenicity and safety of the quadrivalent human papillomavirus vaccine in HIV-1-infected women." Clin. Infect. Dis.. 2014;59(1):127-35.
Lok JJ, Hunt PW, Collier AC, et al. "The impact of age on the prognostic capacity of CD8+ T-cell activation during suppressive antiretroviral therapy." AIDS. 2013;27(13):2101-10.
Cillo AR, Krishnan S, McMahon DK, Mitsuyasu RT, Para MF, Mellors JW. "Impact of chemotherapy for HIV-1 related lymphoma on residual viremia and cellular HIV-1 DNA in patients on suppressive antiretroviral therapy." PLoS ONE. 2014;9(3):e92118.
Marra CM, Zhao Y, Clifford DB, et al. "Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance." AIDS. 2009;23(11):1359-66.
Linas BP, Wang B, Smurzynski M, et al. "The impact of HIV/HCV co-infection on health care utilization and disability: results of the ACTG Longitudinal Linked Randomized Trials (ALLRT) Cohort." J. Viral Hepat.. 2011;18(7):506-12.
Sacktor N, Miyahara S, Evans S, et al. "Impact of minocycline on cerebrospinal fluid markers of oxidative stress, neuronal injury, and inflammation in HIV-seropositive individuals with cognitive impairment." J. Neurovirol.. 2014;20(6):620-6.
Li JZ, Paredes R, Ribaudo HJ, et al. "Impact of minority nonnucleoside reverse transcriptase inhibitor resistance mutations on resistance genotype after virologic failure." J. Infect. Dis.. 2013;207(6):893-7.
Butt AA, Umbleja T, Andersen JW, Sherman KE, Chung RT. "Impact of peginterferon alpha and ribavirin treatment on lipid profiles and insulin resistance in Hepatitis C virus/HIV-coinfected persons: the AIDS Clinical Trials Group A5178 Study." Clin. Infect. Dis.. 2012;55(5):631-8.
Erlandson KMace, Kitch D, Tierney C, et al. "Impact of randomized antiretroviral therapy initiation on glucose metabolism." AIDS. 2014;28(10):1451-61.
Aweeka FT, Rosenkranz SL, Segal Y, et al. "The impact of sex and contraceptive therapy on the plasma and intracellular pharmacokinetics of zidovudine." AIDS. 2006;20(14):1833-41.
Ribaudo HJ, Daar ES, Tierney C, et al. "Impact of UGT1A1 Gilbert variant on discontinuation of ritonavir-boosted atazanavir in AIDS Clinical Trials Group Study A5202." J. Infect. Dis.. 2013;207(3):420-5.
Godfrey C, Schouten JT, Swindells S. "Implementation of HIV-related clinical research in the international setting." J. Acquir. Immune Defic. Syndr.. 2014;65 Suppl 1:S1-2.
Skiest DJ, Krambrink A, Su Z, Robertson KR, Margolis DM. "Improved measures of quality of life, lipid profile, and lipoatrophy after treatment interruption in HIV-infected patients with immune preservation: results of ACTG 5170." J. Acquir. Immune Defic. Syndr.. 2008;49(4):377-83.
Robertson K, Jiang H, Kumwenda J, et al. "Improved neuropsychological and neurological functioning across three antiretroviral regimens in diverse resource-limited settings: AIDS Clinical Trials Group study a5199, the International Neurological Study." Clin. Infect. Dis.. 2012;55(6):868-76.
Williams P, Wu J, Cohn S, et al. "Improvement in lipid profiles over 6 years of follow-up in adults with AIDS and immune reconstitution." HIV Med.. 2009;10(5):290-301.
Kshirsagar SA, Blaschke TF, Sheiner LB, Krygowski M, Acosta EP, Verotta D. "Improving data reliability using a non-compliance detection method versus using pharmacokinetic criteria." J Pharmacokinet Pharmacodyn. 2007;34(1):35-55.
Godfrey CC, Michelow PM, Godard M, et al. "Improving diagnostic capability for HPV disease internationally within the NIH-NIAID Division of AIDS Clinical Trial Networks." Am. J. Clin. Pathol.. 2013;140(6):881-9.
Shire NJ, Rao MB, Succop P, et al. "Improving noninvasive methods of assessing liver fibrosis in patients with hepatitis C virus/human immunodeficiency virus co-infection." Clin. Gastroenterol. Hepatol.. 2009;7(4):471-80, 480.e1-2.
Branch AD, Kang M, Hollabaugh K, Wyatt CM, Chung RT, Glesby MJ. "In HIV/hepatitis C virus co-infected patients, higher 25-hydroxyvitamin D concentrations were not related to hepatitis C virus treatment responses but were associated with ritonavir use." Am. J. Clin. Nutr.. 2013;98(2):423-9.
Tsibris AMN, Sagar M, Gulick RM, et al. "In vivo emergence of vicriviroc resistance in a human immunodeficiency virus type 1 subtype C-infected subject." J. Virol.. 2008;82(16):8210-4.
Krishnan S, Schouten JT, Jacobson DL, et al. "Incidence of non-AIDS-defining cancer in antiretroviral treatment-naïve subjects after antiretroviral treatment initiation: an ACTG longitudinal linked randomized trials analysis." Oncology. 2011;80(1-2):42-9.
Butt AA, Umbleja T, Andersen JW, Chung RT, Sherman KE. "The incidence, predictors and management of anaemia and its association with virological response in HCV / HIV coinfected persons treated with long-term pegylated interferon alfa 2a and ribavirin." Aliment. Pharmacol. Ther.. 2011;33(11):1234-44.
Krishnan S, Wu K, Smurzynski M, et al. "Incidence rate of and factors associated with loss to follow-up in a longitudinal cohort of antiretroviral-treated HIV-infected persons: an AIDS Clinical Trials Group (ACTG) Longitudinal Linked Randomized Trials (ALLRT) analysis." HIV Clin Trials. 2011;12(4):190-200.